Brokerages expect LeMaitre Vascular Inc (NASDAQ:LMAT) to post $0.21 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for LeMaitre Vascular’s earnings. LeMaitre Vascular posted earnings per share of $0.43 during the same quarter last year, which indicates a negative year over year growth rate of 51.2%. The company is expected to report its next quarterly earnings results on Thursday, July 25th.
On average, analysts expect that LeMaitre Vascular will report full year earnings of $0.83 per share for the current year, with EPS estimates ranging from $0.82 to $0.84. For the next fiscal year, analysts anticipate that the company will report earnings of $0.92 per share, with EPS estimates ranging from $0.89 to $0.95. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover LeMaitre Vascular.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02). The company had revenue of $28.48 million during the quarter, compared to the consensus estimate of $27.94 million. LeMaitre Vascular had a return on equity of 16.76% and a net margin of 20.92%. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period last year, the business posted $0.19 EPS.
Several hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp increased its holdings in shares of LeMaitre Vascular by 2.7% during the third quarter. Bank of New York Mellon Corp now owns 253,149 shares of the medical instruments supplier’s stock valued at $9,807,000 after acquiring an additional 6,705 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of LeMaitre Vascular by 7.4% during the third quarter. Teachers Advisors LLC now owns 31,470 shares of the medical instruments supplier’s stock valued at $1,219,000 after acquiring an additional 2,162 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of LeMaitre Vascular by 11.0% during the third quarter. Legal & General Group Plc now owns 33,785 shares of the medical instruments supplier’s stock valued at $1,295,000 after acquiring an additional 3,360 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of LeMaitre Vascular by 5.8% during the third quarter. Vanguard Group Inc. now owns 1,208,742 shares of the medical instruments supplier’s stock valued at $46,826,000 after acquiring an additional 66,427 shares in the last quarter. Finally, Bank of Montreal Can increased its holdings in shares of LeMaitre Vascular by 99.1% during the fourth quarter. Bank of Montreal Can now owns 1,113 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 554 shares in the last quarter. Institutional investors own 77.22% of the company’s stock.
Shares of NASDAQ LMAT traded down $0.13 during mid-day trading on Friday, hitting $25.80. The company had a trading volume of 1,376 shares, compared to its average volume of 81,941. The company has a market cap of $510.04 million, a price-to-earnings ratio of 30.81, a price-to-earnings-growth ratio of 2.65 and a beta of 1.17. LeMaitre Vascular has a 12 month low of $21.79 and a 12 month high of $38.99.
The company also recently declared a quarterly dividend, which will be paid on Thursday, June 6th. Stockholders of record on Wednesday, May 22nd will be given a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 1.32%. The ex-dividend date of this dividend is Tuesday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 40.48%.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Further Reading: Return On Assets
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.